Search Protocols under revision. Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologySarcomasSarcomas (ped.)DiseaseLiver Sarcoma UndifferentiatedRhabdomyosarcomaSoft Tissue SarcomaSubgroupAlveolar Soft Tissue SarcomaAngiosarcomaDermatofibrosarcoma protuberansFibromatosis, aggressiveLeiomyosarcoma, uterineLiposarcomaLiposarcoma, dedifferentiatedRhabdomyosarcomasolitary fibrous tumorSynovial SarcomaICD10C49.-MeSHFibromatosis, AggressiveHemangiosarcomaLeiomyosarcomaLiposarcomaNeoplasms, Connective and Soft TissueRhabdomyosarcoma, EmbryonalSarcoma, SynovialUterine NeoplasmsSequenceGEMC900/DOCE75, Soft Tissue Sarcoma, adj., A (PID1945) -|- DOXO60, B (PID1946)LMS-04: DOXO60/TRAB1.1, Soft Tissue Sarcoma (PID2210) -|- TRAB1.1, Maint. (PID2219)OLAR15/DOXO75, Soft Tissue Sarcoma, C1 (PID845) -|- C2-4 (PID846) -|- C5-8 (PID851) -|- Maint. (PID847)Oncology Group Trial 9514: DOXO20/IFOS2.5/DCRB225/Radiation, Soft Tissue Sarcoma, perioperative (PID2359)PACL90/BEVA15, Soft Tissue Sarcoma (PID1827) -|- BEVA15 (PID1826)PACL200/BEVA15,Soft Tissue Sarcoma (PID1828) -|- BEVA15 (PID1826)SU2C-SARC032: PEMB200/Radiation, Soft Tissue Sarcoma, perioperative (PID2811)VAIA III, Soft Tissue SarcomaVIT-0910: VIT (TMZL125/VNCR2/IRIN50), Soft Tissue Sarcoma, C1 (PID2255) -|- VIT (TMZL150/VNCR2/IRIN50), C2-12 (PID2256).ChemotherapyChemo-substanceAtezolizumabAxitinibBevacizumabCabazitaxelCrizotinibCyclophosphamideDacarbazineDactinomycinDocetaxelDoxorubicinDoxorubicin pegylated liposomalEpirubicinEribulinGemcitabineIfosfamideImatinibIrinotecanMesnaMethotrexateOlaratumabPaclitaxelPazopanibPembrolizumabSelinexorSorafenibSunitinibTazemetostatTemozolomideTrabectedinVinblastineVincristineVinorelbineChemo-substanceAtezolizumabAxitinibBevacizumabCabazitaxelCrizotinibCyclophosphamideDacarbazineDactinomycinDocetaxelDoxorubicinDoxorubicin pegylated liposomalEpirubicinEribulinGemcitabineIfosfamideImatinibIrinotecanMesnaMethotrexateOlaratumabPaclitaxelPazopanibPembrolizumabSelinexorSorafenibSunitinibTazemetostatTemozolomideTrabectedinVinblastineVincristineVinorelbineChemo-substanceAtezolizumabAxitinibBevacizumabCabazitaxelCrizotinibCyclophosphamideDacarbazineDactinomycinDocetaxelDoxorubicinDoxorubicin pegylated liposomalEpirubicinEribulinGemcitabineIfosfamideImatinibIrinotecanMesnaMethotrexateOlaratumabPaclitaxelPazopanibPembrolizumabSelinexorSorafenibSunitinibTazemetostatTemozolomideTrabectedinVinblastineVincristineVinorelbineChemo-substanceAtezolizumabAxitinibBevacizumabCabazitaxelCrizotinibCyclophosphamideDacarbazineDactinomycinDocetaxelDoxorubicinDoxorubicin pegylated liposomalEpirubicinEribulinGemcitabineIfosfamideImatinibIrinotecanMesnaMethotrexateOlaratumabPaclitaxelPazopanibPembrolizumabSelinexorSorafenibSunitinibTazemetostatTemozolomideTrabectedinVinblastineVincristineVinorelbineNo. Substances123 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDexrazoxaneDimetindenFamotidineFosaprepitantGranisetronMesnaPegfilgrastimPyridoxineSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDexrazoxaneDimetindenFamotidineFosaprepitantGranisetronMesnaPegfilgrastimPyridoxineSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDexrazoxaneDimetindenFamotidineFosaprepitantGranisetronMesnaPegfilgrastimPyridoxineSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDexrazoxaneDimetindenFamotidineFosaprepitantGranisetronMesnaPegfilgrastimPyridoxineNo. Substances1234568Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseneoadjuvantneoadjuvant / adjuvantseveral possibleTherapy intentioncurativecurative or palliativepalliativeRisksAbdominal PainAllergic ReactionAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityColitisConstipationCystitisDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHepatotoxicityHyperbilirubinemiaHyperglycemiaHypertensionHyperthyroidismHypoalbuminemiaHypokalemiaHyponatremiaHypotensionHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesIncrease Creatinine PhosphokinaseInfectionsLeukopeniaMucositisMyalgiasNauseaNeuropathyNeutropeniaOral MucositisPainPleural EffusionPneumoniaPneumonitisPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventVisual DisturbancesVomiting only studiesPublicationAuthorAgulnik MAntman KBitz UBui NBusea JChen APChugh RDavis EDefachelles ASDemetri GDDickson MGarcıá-del-Muro XGounder MGounder MMGrobmyer SRGronchi AGrünwald VHensley MLJudson IKoscielniak E, Klingebiel TKraybill WGMaki RMowery YMOosterom ATPalassini EPark MSPautier PPenel NRutkowski PSanfilippo RScheinberg T Schöffski PStacchiotti STap WTreuner J. Koscielniak Evan der Graaf WTWilky BAZalupski MZucali PDiseaseAggressive Fibromatose (Desmoid), neu diagnostiziert oder rezidiviert, nicht operabel, ECOG 0-1Aggressive Fibromatose, lokal fortgeschrittenAlveoläres Weichteilsarkom, nicht resezierbar oder metastasiert, ab 2 JahreAngiosarkom, bis zu 2 Vortherapien, ECOG 0-1Angiosarkom oder epitheloides Hämangioendotheliom, bis zu 3 Vortherapien, ECOG 0-1Dermatofibrosarcoma protuberans, lokal fortgeschritten oder metastasiert, teilweise mit fibrosarcomatöser TransformationEntdifferenziertes Liposarkom, nach 2-5 Vortherapien, ECOG 0-1Entzündlicher Myofibroblastentumor (inflammatorischer Myofibroblastentumor), lokal fortgeschritten, inoperabel, ALK+Fortgeschrittener solitärer fibröser Tumor, ECOG 0-3Fortgeschrittenes oder metastasiertes epitheloides Sarkom, ECOG 0-2fortgeschrittenes oder metastasiertes Leiomyosarkom/Liposarkom, Erstliniefortgeschrittenes oder metastasiertes Weichteilsarkom, Zweitlinie nach Anthrazyklin oder Ifosfamid oder Kontrainidikation, ECOG 0-2fortgeschrittenes Weichteilsarkom, ECOG 0-1fortschreitendes Weichteilsarkom nach anthrazyklinhaltiger Therapie, high-grade uterines Leiomyosarkom, FIGO I-IIIA, ECOG 0-1, adjuvantHochmalignes Weichteilsarkom (Grad 2-3), fortgeschritten oder metastasiert, ECOG 0-1, 18-60 JahreLeiomyosarkom, metastasiert oder lokal fortgeschritten, inoperabel, ErstlinieLiposarkom, entdifferenziert, metastasiert oder lokal fortgeschritten, ECOG 0-1, 18-75 J., max. 1 VortherapieLiposarkom oder Leiomyosarkom, nicht resektabel oder metastasiert, Rezidiv nach Anthrazyklin und Ifosfamid (in Kombi oder sequentiell), ECOG 0-1lokalisiertes Weichteilsarkom, Grad 3 oder 2 mit 50% Nekrosen, ECOG < 1metastasiertes oder fortgeschrittenes Angiosarkom, Rezidivtherapie, ECOG 0-2metastasiertes oder nicht-resezierbares Weichteilsarkom, ECOG 0-2Metastasiertes oder nichtresezierbares Leiomyosarkom, nach Doxorubicin oder Erstlinie, ECOG 0-2metastasiertes Weichteilsarkom, 2.- 5.-Linie, ECOG 0-1metastasiertes Weichteilsarkom, Anthrazyklinnaiv, ECOG 0-2metastasiertes Weichteilsarkom, Erstliniemetastasiertes Weichteilsarkom, Erstlinie, über 60 Jahre, ECOG 0-2Myxoides Liposarkom (HG-MLPS) G3, ab 5cm Größe, cM0Neo/adjuvante Therapie des Weichteilsarkoms mit niederiger Hospitalisierungsrate, ECOG 0-1, T 2b, G2-3Neo/adjuvante Therapie des Weichteilsarkoms mit niedriger Hospitalisierungsrate, ECOG 0-1, T 2b, G2-3Pleomorphes dedifferenziertes Sarkom, oder Liposarkom der Extremität, cT2 cN0 cM0, 12 J. oder älter, perioperativ, ECOG 0-1Rezidivierendes oder progressives Weichteilsarkom, ECOG 0-2, ab 10 JahrenRezidiviertes oder fortschreitendes Weichteilsarkom, ECOG 0-2Sarkome der Extremitäten und des Körperstammes, Tumordurchmesser >8 cm, high-grade, high-riskSolitärer fibröser Tumor oder metastasiertes HämangioperizytomSporadische desmoide Fibromatose (aggressive Fibromatose)Weichteilsarkom, alveoläres WeichteilsarkomWeichteilsarkom, alveoläres Weichteilsarkom, ab 16 J., ECOG 0-1, ab ZweitlinieWeichteilsarkom, HRWeichteilsarkom, Kinder, Jugendliche und junge ErwachseneWeichteilsarkom, neoadjuvantWeichteilsarkom, rezidiviertWeichteilsarkom, Rezidiv oder metastasiertWeichteilsarkom, Rhabdomyosarkom, Leiomyosarkom, Erstlinie, ECOG 0-2Weichteilsarkom, SynovialsarkomWeichteilsarkom schnell fortschreitend, ECOG 0-2wiederkehrendes, lokal fortgeschrittenes oder metastasiertes Lipo-/ Leiomyosarkom, ECOG 0-2OriginA Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study, TAXOGEM studyCWS 2002 Protokoll der Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH)Dana-Farber Cancer Institute, Boston, MADepartement de Cancerologie Generale, Unite de Biostatistiques, and Departement d’Imagerie Medicale, Centre Oscar Lambret, ANGIOTAX studyDepartment of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, BelgiumDepartment of Medical Oncology and Hematology, Istituto Clinico Humanitas, ItalyDepartment of Medicine, Memorial Sloan-Kettering Cancer Center New York, Sarcoma Alliance for Research Through Collaboration Study 002Department of Surgery, Cancer Medicine and Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ISG-STS 1001Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA, Oncology Group Trial 9514Division of Cancer Medicine, The University of Texas MD Anderson Cancer, USADivision of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, ChicagoDivision of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United StatesDivision of Hematology/Onkology, University of Michigan, Ann Arbor, MI, United StatesEORTC Soft Tissue and Bone Sarcoma GroupEORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group; PALETTE StudieEuropean Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupFondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyFondazione IRCCS Istituto Nazionale Tumori, Milan, ItalyFondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale dei Tumori, Milan, ItalyGesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH), Studienprotokoll CWS-GuidanceHELIOS Klinikum Bad Saarow, Sarcoma Center Berlin-Brandenburg, Bad Saarow, GermanyHospital General de Asturias, Oviedo, Spain, E.O.R.T.C. Soft Tissue and Bone Sarcoma GroupINSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France, VIT-0910 trialInstitut Català d’Oncologia L’Hospitalet, a Spanish Group for Research on Sarcomas StudyInstitut Gustave-Roussy, Villejuif, France, LMS-04 trialIRCCS Fondazione Istituto Nazionale TumoriIstituto Nazionale Tumori, Milan, ItalyMaria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Warsaw PolandMedical School Hannover, Hannover, GermanyMemorial Sloan-Kettering Cancer Center, New York, SARC 005 trialMemorial Sloan-Kettering Cancer Center New York, NYMemorial Sloan Kettering Cancer Center, New York, USAMemorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, USAMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New YorkMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, SEAL trialNational Cancer Institute, BethesdaRoyal Marsden Hospital London, UK, EORTC Soft Tissue and Bone Sarcoma GroupSouthwest Oncology Group studyStanford Cancer Institute, Stanford, CA, USAThe Trabectedin Global Sarcoma Study GroupThe University of Texas MD Anderson Cancer Center, Houston, TexasUniversity Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium, EORTC trial 90101 CREATEUniversity of Miami Miller School of Medicine, Miami, FL, USAUniversity of Michigan, Ann Arbor, USAUPMC Hillman Cancer Center-University of Pittsburgh, Pittsburgh, PA, USA, SU2C-SARC032 trialProtocols in Revision 59 protocols foundAtezolizumab 1200, Soft Tissue Sarcoma (PID2455 V1.0)Bevacizumab 15, Soft Tissue Sarcoma (PID1826 V1.0)Cabazitaxel 25, Soft Tissue Sarcoma (PID2172 V1.0)Crizotinib 250, Soft Tissue Sarcoma (PID2047 V1.0)Dacarbazine 1200, Soft Tissue Sarcoma (PID1211 V1.0)Dacarbazine 300, Soft Tissue Sarcoma (PID1212 V1.1)Doxorubicin 15 / Dacarbazine 250, Soft Tissue Sarcoma (PID1214 V1.1)Doxorubicin 20 / Ifosfamide 2.5 / Dacarbazine 225 / Radiation, Soft Tissue Sarcoma, perioperative (PID2359 V1.1)Doxorubicin 25 / Ifosfamide 2.5, Soft Tissue Sarcoma (PID506 V1.2)Doxorubicin 25 / Ifosfamide 3, Soft Tissue Sarcoma neoadjuvant (PID2545 V1.0)Doxorubicin 60 / Dacarbazine 750, Soft Tissue Sarcoma (PID1215 V1.0)Doxorubicin 60 / Trabectedin 1.1, Soft Tissue Sarcoma (PID2210 V1.0)Doxorubicin 60, Soft Tissue Sarcoma, adjuvant, Part B (PID1946 V1.0)Doxorubicin 75 / Dacarbazine 400, Soft Tissue Sarcoma (PID1213 V1.1)Doxorubicin 75 / Ifosfamide 2.5, Soft Tissue Sarcoma neo/adjuvant (PID575 V1.2)Doxorubicin 75, Soft Tissue Sarcoma (PID507 V1.0)Epirubicin 60 / Ifosfamide 3, Soft Tissue Sarcoma neoadjuvant (PID976 V2.0)Eribulin 1.23, Soft Tissue Sarcoma (PID826 V1.1)Gemcitabine 1000, Soft Tissue Sarcoma (PID2973 V1.0)Gemcitabine 1200, Soft Tissue Sarcoma (PID2974 V1.0)Gemcitabine 1800 / Dacarbazine 500, Soft Tissue Sarcoma (PID1181 V1.0)Gemcitabine 900 / Docetaxel 100, Soft Tissue Sarcoma (PID570 V1.0)Gemcitabine 900 / Docetaxel 100, Soft Tissue Sarcoma neo/adjuvant (PID576 V1.0)Gemcitabine 900 / Docetaxel 75 / Bevacizumab 15, Soft Tissue Sarcoma (PID573 V1.0)Gemcitabine 900 / Docetaxel 75, Soft Tissue Sarcoma, adjuvant, part A (PID1945 V1.0)Ifosfamide 3, Soft Tissue Sarcoma (PID509 V1.1)Ifosfamide 7, Soft Tissue Sarcoma, neoadjuvant (PID2546 V1.0)Imatinib 300, Soft Tissue Sarcoma (PID2044 V1.0)Imatinib 400, Soft Tissue Sarcoma (PID2048 V1.0)Methotrexate 30 / Vinblastine 6, Soft Tissue Sarcoma (PID2042 V1.0)Methotrexate 50 / Vinorelbine 20, Soft Tissue Sarcoma (PID2043 V1.0)Olaratumab 15 / Doxorubicin 75 - Olaratumab 15 maintenance, Soft Tissue Sarcoma (PID847 V1.0)Olaratumab 15 / Doxorubicin 75, Soft Tissue Sarcoma, Cycle 1 (PID845 V1.0)Olaratumab 15 / Doxorubicin 75, Soft Tissue Sarcoma, Cycle 2-4 (PID846 V1.0)Olaratumab 15 / Doxorubicin 75, Soft Tissue Sarcoma, Cycle 5-8 (PID851 V1.0)Paclitaxel 200 / Bevacizumab 15, Soft Tissue Sarcoma (PID1828 V1.0)Paclitaxel 80, Soft Tissue Sarcoma (PID1207 V1.1)Paclitaxel 90 / Bevacizumab 15, Soft Tissue Sarcoma (PID1827 V1.0)PAED CWS guidance, Methotrexate 20 / Vinblastine 3, fibromatosis, aggressive (PID1315 V1.0)PAED CWS-Guidance, VAC - Vincristine 1.5 / Dactinomycin 1.5 / Cyclophosphamide 20, fibromatosis, aggressive (PID1312 V1.0)Pazopanib 800, Soft Tissue Sarcoma (PID511 V1.0)Pazopanib 800, Soft Tissue Sarcoma, first-line (PID1665 V1.0)Doxorubicin Pegylated Liposomal 50, Soft Tissue Sarcoma (PID1200 V1.0)Pembrolizumab 200 / Axitinib 5, Soft Tissue Sarcoma (PID2460 V1.0)Pembrolizumab 200 / Radiation, Soft Tissue Sarcoma, perioperative (PID2811 V1.0)Pembrolizumab 200, Soft Tissue Sarcoma (PID2461 V1.0)Selinexor 60, Soft Tissue Sarcoma (PID2053 V1.0)Sorafenib 400, Aggressive Fibromatosis (PID699 V1.0)Sunitinib 37.5, Soft Tissue Sarcoma (PID2046 V1.0)Tazemetostat 800, Soft Tissue Sarcoma (PID2860 V1.0)Temozolomide 150 / Bevacizumab 5, Soft Tissue Sarcoma (PID2045 V1.0)Trabectedin 1.3, Soft Tissue Sarcoma, neoadjuvant (PID2544 V1.0)Trabectedin 1.5, Soft Tissue Sarcoma (PID510 V1.0)VAIA III Block 1 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID657 V1.2)VAIA III Block 2 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID659 V1.3)VAIA III Block 3,4,6 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID660 V1.2)VAIA III Block 5,7,8,9 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID661 V1.3)VIT (Temozolomide 125 / Vincristine 2 / Irinotecan 50), Soft Tissue Sarcoma, Cycle 1 (PID2255 V1.1)VIT (Temozolomide 150 / Vincristine 2 / Irinotecan 50), Soft Tissue Sarcoma, Cycle 2-12 (PID2256 V1.1)
